Current status of research on fibrates in treatment of primary biliary cholangitis / 临床肝胆病杂志

ABSTRACT

At present, ursodeoxycholic acid (UDCA) and obeticholic acid (OCA) are approved by FDA for the treatment of primary biliary cholangitis (PBC). New drugs are urgently needed for the patients who have inadequate response to UDCA or cannot tolerate pruritus, a common side effect of OCA. In recent years, a large number of basic experiments and clinical studies have shown that fibrates have a good clinical effect in the treatment of PBC. This article reviews the advances in the mechanism and clinical application of fibrates in the treatment of PBC.